CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
about
Cancer-Associated Myeloid Regulatory CellsGenetics and biology of pancreatic ductal adenocarcinomaKey players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cellsAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyTherapeutic potential of chemokine signal inhibition for metastatic breast cancerMyeloid Cells as Targets for Therapy in Solid TumorsFunctional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer ProgressionTargeting cancer with kinase inhibitorsTargeting tumor-associated macrophages to combat pancreatic cancerPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsGenetically engineered mouse models in oncology research and cancer medicineAlong the Axis between Type 1 and Type 2 Immunity; Principles Conserved in Evolution from Fish to MammalsT cell exclusion, immune privilege, and the tumor microenvironmentMacrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Microenvironmental regulation of therapeutic response in cancerImmunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Chemotherapy and tumor microenvironment of pancreatic cancer.Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.Classification of current anticancer immunotherapiesInduction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceMITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.Increased Expression of CSF-1 Associates With Poor Prognosis of Patients With Gastric Cancer Undergoing Gastrectomy.Diverse in vivo effects of soluble and membrane-bound M-CSF on tumor-associated macrophages in lymphoma xenograft model.Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsColony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Antagonizing Integrin β3 Increases Immunosuppression in Cancer.Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer
P2860
Q26750382-0324D8D2-A63A-46B1-A12F-4192C7A11B04Q26765438-5FF9DFB0-D908-49C0-88A8-8F4871F7C528Q26766065-DD18889E-B90B-4AB0-956F-12E19E9618B5Q26774312-EFEDD895-CEAC-4080-B830-4C2F3165CC89Q26779184-B6673867-EC08-407C-8381-4E840337BA2EQ26798116-48E85678-4BAE-4319-99C6-BDD892ED9B92Q26801832-2205BC76-DF25-47C3-83CF-A33F9CF5DD7CQ26863784-333359C5-0925-4BF3-A936-F85F78B24D26Q26865765-E30EC89B-E9FE-4F1C-863E-492E4E885529Q28076103-70E035F0-300F-412F-8F69-0CCC7E6644FBQ28076161-A99B21C5-11A7-4ABC-BCCF-D349CE6B31BAQ28079323-4645CF66-1AA4-4F9A-BE8F-05CA274FF11CQ28083360-66B9D05C-61CB-42BE-806B-42F3926D7210Q28259872-D227B5B5-688D-4E55-BC20-25022DEA5692Q30278005-B779D43C-5D39-45BA-A81C-836967952316Q33654609-38A32195-B822-48C2-8037-CEA98DDCC5B1Q33779875-2C370D15-5A32-4D15-8434-78DB2305C717Q33876637-68A15C34-7B20-4BC7-A07B-27F991F8B841Q35090032-D4A7FEDF-0673-4B1C-8BE4-71A21A8035D1Q35149637-26C4BC5D-DAA3-46EC-84A9-29B259C2D9A5Q35329190-309D0780-53C2-415D-8ECE-7ADCD85A222EQ36125878-9EC8CA5B-7414-4661-A40E-92B608A3EF1DQ36320144-0F42FC81-0401-44AF-A01E-45523D1A016FQ36390700-FC8A2C3D-553A-4797-8A83-582200166A67Q36414357-D2C4CF5B-4E22-4D51-B973-14DE7339829FQ36436992-10F2CB82-B9A5-4892-B0DA-7F21C97D5116Q36459188-6A375ECD-2186-4158-8518-DEE827D6F463Q36663831-FF62D8B2-1F08-479D-8D94-A96B27686E2DQ36738826-E72E3FE0-6764-4A0E-8958-1D0CDDD132EDQ36821239-2DFBC080-27B7-4449-8B55-86DD81453189Q36863121-B7196EF3-2558-455E-9F09-4F2C58C28A3EQ36869880-85C2E582-0D5C-4567-9E8B-4E8128E5568FQ36893213-6D2A61DE-ABB5-469D-A51F-DDD445FD1430Q36963605-BFD62A08-A753-4835-8ACA-8B2D7B3C315DQ37017190-AD154022-6534-4545-A72B-B6C7C057E0D8Q37029731-3F6EA086-41C6-488C-81BE-C30986A6063DQ37072889-7AD8FFD0-F798-4DEA-822A-88BCD0EEB247Q37094368-8E292B4A-833B-4070-8E6B-A87F5CDC27D6Q37109800-18CCC22F-30DF-4C08-AC4B-4D973A1058FDQ37113485-FD55EFC4-0C2E-4E9E-9540-E582135A0324
P2860
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@ast
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@en
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@nl
type
label
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@ast
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@en
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@nl
prefLabel
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@ast
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@en
CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.
@nl
P2093
P2860
P50
P1433
P1476
CSF1/CSF1R blockade reprograms ...... py in pancreatic cancer models
@en
P2093
Andrea Wang-Gillam
Brett L Knolhoff
David C Linehan
David G DeNardo
Jingqin Luo
S Peter Goedegebuure
Timothy M Nywening
P2860
P304
P356
10.1158/0008-5472.CAN-13-3723
P407
P577
2014-07-31T00:00:00Z